secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bioventus Inc. (BVS)
CIK:        0001665988
Form:       8-K
Filed at:   2023-03-31T23:59:59+00:00
Accession:  0001628280-23-010022
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bioventus Q4 net loss $44.9M; FY22 net loss $213.4M; removes $350M CartiHeal liabilities
--------------------------------------------------------------------------------

- Net sales Q4 $125.8M (-3.5% YoY); Pain Treatments down 25.4% on higher rebate claims.
- FY22 net loss $213.4M vs $9.6M income in 2021; includes $189.2M non-cash impairment.
- Adjusted EBITDA Q4 $15.2M vs $28.5M; FY22 $66.3M vs $80.8M.
- Settlement on Feb 28, 2023 removed $350M of CartiHeal liabilities; credit agreement amended for covenant relief.
- Cash $31.8M, debt $418.1M at Dec 31, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1665988/000162828023010022/0001628280-23-010022-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1665988/000162828023010022/bvs-20230331.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-010022

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer